Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 439Stomach Neoplasms 248Carcinoma, Hepatocellular 246Rectal Neoplasms 211Colonic Neoplasms 204Pancreatic Neoplasms 172Esophageal Neoplasms 113Neoplasm Metastasis 75Liver Neoplasms 71Esophageal Squamous Cell Carcinoma 64Neoplasms 63Gastrointestinal Stromal Tumors 36Cholangiocarcinoma 36Gastrointestinal Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 25Gallbladder Neoplasms 25Adenocarcinoma Of Esophagus 24Biliary Tract Neoplasms 23Anus Neoplasms 22Adenocarcinoma 21Recurrence 19Bile Duct Neoplasms 19Breast Neoplasms 18Digestive System Neoplasms 17Lung Neoplasms 13Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma 11Digestive System Diseases 10Peritoneal Neoplasms 9

Interventions

Taxes 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Borderline Resectable Pancreatic Cancer × Gastrointestinal × Clear all
NCT04617821 2022-01-28

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Fudan University

Phase 3 Unknown
300 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡